ABTA Funding Supports Development of Two New Malignant Glioma Drugs
In just three years
since the launch of the American Brain Tumor
Association’s Discovery Grant program, we are pleased to announce that
our funding has aided the development of two new brain tumor drugs that target
malignant gliomas such as glioblastoma multiforme (GBM). Read more about these research
Updates from the Society for Neuro-Oncology Meeting
Staff from the ABTA joined more than 2,000 healthcare professionals last month in San Francisco for the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology and Society for Neuro-Oncology (SNO) Annual Meeting. Four days of scientific and clinical presentations addressed current best practices in treating brain tumors, quality of life and symptom management, and new areas of research interest. The meeting offered opportunities for collaborative dialogue between industry, scientists, clinicians, federal funders, patient advocates and philanthropy organizations.
Among the highlights:
- Discussions of the studies needed to determine the most beneficial uses of bevacizumab (Avastin)
- The current “state of the science” in biologic markers
- Emerging image-based technologies that measure mineral content and ph in the tissue around the tumor to monitor for tumor regrowth
- Coming changes in the way tumors are classified or “grouped” based on their biologic differences
- Early observations from ongoing clinical trials (visit the ABTA’s TrialConnect for more information on open trials)
- A growing interest among clinician scientists in immune therapies
The ABTA sponsored a Quality of Life track which provided symptom management and palliative care tools for allied health professionals working with patients and their caregivers, while many ABTA-funded researchers shared their study data with other researchers via podium and poster presentations.
Webinar: Fertility Concerns for the Brain Tumor
Brain tumor survivors
may face long-term reproductive challenges as a result of their treatment. Our
webinar on Wednesday,
Dec. 11 at 2:00 p.m. CST will explore the effects various types
of treatments can have on both male and female fertility, along with options
for preserving and restoring fertility. The webinar will be co-presented by
Lisa Kolp, MD and Pravin Rao, MD, both of Johns Hopkins University. There
will be time for Q & A with Dr. Kolp and Dr. Rao immediately following the
for “Fertility Concerns for the Brain Tumor Survivor.”
Infertility is just one of many potential long-term effects of brain tumor treatment. Read more about how side and late effects can impact survivorship in the ABTA’s Headlines newsletter.
Stress? Turn to the ABTA’s CareLine
Caring for a loved one with a brain tumor can be overwhelming — and the holiday season may lead to increased stress as families struggle to make life feel as normal as possible. The ABTA’s licensed health care professionals can help you better understand and manage the stress and emotions you may be experiencing. For a one- on-one consultation call the ABTA Careline at 800-886-ABTA (2282); or email your questions or concerns to email@example.com.
The Giving Season
to donating to the ABTA's annual fund,
there are other ways you can support the ABTA:
- Purchase our
Holiday Cards and 50 percent of
your order will be donated to the ABTA. There are dozens of designs to
choose from starting at $29 per box of 25.
- Choose the ABTA
for your CFC Campaign now through January 15. If you are a
federal employee or member of the U.S. military, your registration deadline for the Combined
Federal Campaign (CFC)
has been extended to January 15. Participating
in the CFC allows you to deduct funds from your paycheck to be donated
directly to the ABTA. Select the American Brain Tumor Association
(CFC#11033) on the CFC form, and be sure to check the box to release your
information to the ABTA.
- Double your donations with a Matching Gift. Learn if your employer will match your gift by using our Employer Search web feature.
- Enroll in
Payroll Giving. Many corporate workplaces offer charitable
payroll deductions. Talk to your HR representative about opportunities at
your company for payroll giving such as choosing the ABTA through a United
We’d Like to Hear from You
We are in the process of updating our database and reviewing the effectiveness of our outreach efforts. Your participation in a brief online survey will help us to more effectively provide information that is of interest to you in a way that is the most convenient and preferable for you. Visit www.abta.org/survey to complete the survey.
Extended Temozolomide Treatment Cycle Shows No Survival
Improvement for Newly Diagnosed GBM
Standard of care for patients with newly diagnosed glioblastoma (GBM) is surgery
and radiotherapy with concurrent temozolomide (Temodar). An international
collaboration recently studied the possible effects of extended temozolomide
treatment cycles on the survival of more than 800 newly diagnosed GBM patients.
In addition to longer use of the drug, the study also looked at the status of
the MGMT gene in patients’ tumor tissue. While the researchers found that
prolonged use of temozolomide did not extend survival, MGMT status did provide
information about patient response to treatment and survival. Read the abstract in the November 2013 issue of Journal of Clinical Oncology.
Review of Cerebellar Mutism in Children
transient lack of ability to speak following removal of tumors located in the
posterior fossa of the brain (the bottom, back, lower part of the brain) can be
a common but very worrisome consequence of surgery. Some articles estimate that
24% of children undergoing surgery for medulloblastoma--especially when the
tumor is located near the brain stem--may
experience this sudden onset speech impairment. A review article written by a
research team in Greece addressed the incidence of this mutism, why it is
thought to occur, risk factors, and the need for parental counseling prior to
surgery. While this effect is often of short duration, it may have longer term
impact on the child’s speech, memory processing and reasoning. Read the abstract in the December 2013 issue of Journal of Neurosurgery: Pediatrics.